
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Information and topics of special interest to psychiatry residents and early career psychiatrists can be found on the Resident's Corner page. We invite you to visit.
Information and topics of special interest to psychiatry residents and early career psychiatrists can be found on the




